The global cancer biomarkers market is projected to reach USD 28.2 billion by 2026 from USD 12.4 billion in 2021, at a CAGR of 17.7% during the forecast period. Growth in the cancer biomarkers market is mainly driven by factors such as the increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers. However, patent protection of cancer biomarkers and limited battery life are the major factors hampering the growth of this market.